Here’s what you should know:
1. Takeda could sell Shire’s eye-disease treatment, Xiidra, and its hypoparathyroidism treatment, Natpara.
2. Analysts believe the two drugs could return up to $5 billion if sold.
3. The acquisition is expected to close in March 2019 if approved.
More articles on supply chain:
Mackinaw Surgery Center recognized by SPH Analytics — 3 insights
5 must-read articles for GI physicians this week: Sept. 6-12
How one ASC reduced infection rates while adding total joint procedures
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
